ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Pass Discusses Resistance in Mesothelioma

Harvey I. Pass, MD
Published: Tuesday, Jul 29, 2014

Harvey I. Pass, MD, director, Thoracic Surgery, Thoracic Oncology, NYU Langone Medical Center, discusses treatment resistance in mesothelioma.

Researchers are trying to determine the difference between cells that are resistant to mesothelioma treatment and those that are not. Only about 4% of mesothelioma cells have unique properties that allow them to survive treatment with pemetrexed, stress conditions, or radiation therapy.

When the majority of mesothelioma tumor cells are killed, these unique cells will not respond — they will stay behind and repopulate the tumor, Pass says.

Harvey I. Pass, MD, director, Thoracic Surgery, Thoracic Oncology, NYU Langone Medical Center, discusses treatment resistance in mesothelioma.

Researchers are trying to determine the difference between cells that are resistant to mesothelioma treatment and those that are not. Only about 4% of mesothelioma cells have unique properties that allow them to survive treatment with pemetrexed, stress conditions, or radiation therapy.

When the majority of mesothelioma tumor cells are killed, these unique cells will not respond — they will stay behind and repopulate the tumor, Pass says.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x